ARTICANZ - Beta (ver 0.9)
Annotated Registry of Trials in Cancer, Australia and New Zealand Ed.
- Results - catype/medical-oncology/hepatic/advanced-metastatic
Home
By cancer type
By drug class
By site
Data
FAQ
About
⚠
ARTICANZ provides informational content about cancer drug trials in Australia/NZ that is updated weekly but may not be completely accurate, and should not replace medical advice from qualified healthcare professionals. The platform is intended to be useful, providing information "as is" without warranties. Non-medical users must always consult healthcare providers for all clinical decisions.
Search results
Gastrointestinal (Upper) / Hepatic - Advanced/metastatic
18
trial(s) found.
NCT06910657
Advanced
Phase 1
Not yet recruiting
A First-in-human, Phase I, Multi-center, Open-label, Dose-escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Evidence of Antitumor Activity of IDOV-Immune in Adult Participants With Advanced Solid Tumors (
VM-002-101
)
oncolytic virus,undisclosed mechanism
Bladder cancer
Breast cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Gastric cancer
Head and neck cancer
Hepatocellular carcinoma
Lung cancer
Melanoma
Oesophageal cancer
Ovarian cancer
Pancreatic cancer
Prostate cancer
Sarcoma
NSW
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
VIC
3004 - Melbourne, Southbank - Alfred Health
NCT06533332
Advanced
Phase 1
Recruiting
A First-in-Human, Phase 1 Safety, Tolerability, Pharmacokinetic, and Preliminary Efficacy Study of Escalating Doses of ERX-315 in Participants With Advanced Solid Tumors (
ERX-315-101
)
benzamide,ER alpha-targeting
Breast cancer
Endometrial cancer
Hepatocellular carcinoma
Ovarian cancer
Pancreatic cancer
Solid tumour
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2109 - North Ryde - Macquarie University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
NCT06478693
Advanced
Phase 1
Recruiting
A Phase 1, Open-Label, First-in-Human, Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of MT-303 in Adults With Advanced or Metastatic GPC3-Expressing Cancers, Including Hepatocellular Carcinoma (
MTX-GPC3-303
)
GPC3-targeting lipid-nanoparticle CAR mRNA
GPC3-targeting lipid-nanoparticles
Hepatocellular carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
VIC
3004 - Melbourne, Southbank - Alfred Health
QLD
4102 - Woolloongabba - Integrated Clinical Oncology Network (ICON) Pty Ltd
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT06427941
Advanced
Phase 1
Recruiting
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B2033, Alone or in Combination With Tislelizumab, in Participants With Selected Advanced or Metastatic Solid Tumors (
BGB-B2033-101
)
anti-GPC3 monoclonal antibody
anti-PD-1 monoclonal antibody
Gastric cancer
Hepatocellular carcinoma
Solid tumour
Squamous non-small-cell lung cancer
Yolk sac tumour
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT06242470
Advanced
Phase 1
Recruiting
A Phase 1/1b First-in-Human, Open Label, Dose Escalation and Cohort Expansion Study of MGC026 in Participants With Advanced Solid Tumors (
CP-MGC026-01
)
anti-B7H3 antibody-drug conjugate
Bladder cancer
Cancer
Castrate-resistant prostate cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Gastric cancer
Gastroesophageal cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Pancreatic cancer
Platinum resistant ovarian cancer
Sarcoma
Small-cell lung cancer
Solid tumour
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
QLD
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital
SA
5037 - Kurralta Park - Icon Cancer Centre Adelaide
NCT06084481
Advanced
Phase 1
Recruiting
A Phase 1 Open-Label Study to Evaluate the Efficacy and Safety of ABBV-400 in Select Advanced Solid Tumor Indications (
M24-427
)
anti-cMET antibody-drug conjugate
Biliary tract cancer
Breast cancer
Epithelial Ovarian Cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Oesophageal squamous cell carcinoma
Pancreatic adenocarcinoma
Triple-negative breast cancer
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
NCT05908786
Curative
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Platform Study Evaluating The Efficacy and Safety of Neoadjuvant Immunotherapy Combinations in Patients With Surgically Resectable Hepatocellular Carcinoma (MORPHEUS-NEO HCC) (
GO44457
)
Atezolizumab
Bevacizumab
Tiragolumab
Tobemstomig
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
Hepatocellular carcinoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT05411133
Advanced
Phase 1
Recruiting
A Phase 1, First-in-human Study of Cabotamig (ARB202), Bispecific Antibody to CDH17 and CD3 in Advanced Gastrointestinal Malignancies (
A001
)
bispecific T-cell engager,CDH17-targeting
Cholangiocarcinoma
Colorectal adenocarcinoma
Gastric cancer
Gastrointestinal cancer
Hepatocellular carcinoma
Oesophageal adenocarcinoma
Pancreatic cancer
NSW
2217 - Kogarah - St George Private Hospital
SA
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT04524871
Advanced
Phase 1 / Phase 2
Recruiting
A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatment Combinations in Patients With Advanced Liver Cancers (
Morpheus-Liver
)
ADG126
Atezolizumab
Bevacizumab
HIF2a inhibitor
NKT2152
PPAR-alpha inhibitor
TPST-1120
Tiragolumab
Tobemstomig
Tocilizumab
anti-CTLA-4 monoclonal antibody
anti-IL-6 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
bispecific PD-1/LAG3 antibody
cancer therapy
cancer therapy,CTLA4-targeting
cancer therapy,HIF2a-targeting
cancer therapy,IL-6-targeting
cancer therapy,LAG3-targeting
cancer therapy,PD-1-targeting
cancer therapy,PD-1/PD-L1-targeting
cancer therapy,PD-L1-targeting
cancer therapy,PPAR-alpha-targeting
cancer therapy,TIGIT-targeting
cancer therapy,VEGF-targeting
immune checkpoint blockade
immune checkpoint blockade,CTLA4-targeting
immune checkpoint blockade,LAG3-targeting
immune checkpoint blockade,PD-1-targeting
immune checkpoint blockade,PD-L1-targeting
immune checkpoint blockade,TIGIT-targeting
immuno-oncology therapy,CTLA4-targeting
immuno-oncology therapy,IL-6-targeting
immuno-oncology therapy,LAG3-targeting
immuno-oncology therapy,PD-1-targeting
immuno-oncology therapy,PD-L1-targeting
immuno-oncology therapy,TIGIT-targeting
immuno-oncology therapy,VEGF-targeting
Hepatocellular carcinoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NCT03821935
Advanced
Phase 1
Recruiting
A Phase 1 First-in Human, Multi-Center, Open Label Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and RP2D of Livmoniplimab (ABBV-151) as a Single Agent and in Combination With Budigalimab (ABBV-181) in Subjects With Locally Advanced or Metastatic Solid Tumors (
M19-345
)
anti-GARP monoclonal antibody
anti-PD-1 monoclonal antibody
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Pancreatic adenocarcinoma
Triple-negative breast cancer
Urothelial carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
ACTRN12623000798662
Advanced
Phase 1 / Phase 2
Recruiting
A Phase 1/2, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Clinical Activity of BOS-342 in Patients with Hepatocellular Carcinoma (
HCC
) and other GPC3-expressing Tumors
bispecific GPC3/4-1BB antibody
Cancer
Hepatocellular carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
2050 - Camperdown - Chris O'Brien Lifehouse
SA
5042 - Bedford Park - Flinders Medical Centre
ACTRN12621001444875
Advanced
Phase 2
Recruiting
A randomised controlled trial of Standard Of Care versus RadioAblaTion in Early Stage HCC (The SOCRATES HCC Study) (
The-SOCRATES-HCC-Study
)
Radiotherapy
cancer therapy
Hepatocellular carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre
VIC
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health
3128 - Box Hill - Box Hill Hospital - Eastern Health
QLD
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre
4102 - Woolloongabba - Princess Alexandra Hospital
4215 - Southport - Gold Coast University Hospital
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Flinders Medical Centre
WA
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre
6150 - Murdoch - Fiona Stanley Hospital
NCT05904886
Advanced
Phase 3
Active not recruiting
A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating Atezolizumab and Bevacizumab, With or Without Tiragolumab, in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (
SKYSCRAPER-14
)
anti-PD-L1 monoclonal antibody
anti-TIGIT monoclonal antibody
anti-VEGF monoclonal antibody
placebo
Hepatocellular carcinoma
NZ
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre
NCT05858736
Advanced
Phase 1
Active not recruiting
Safety, Pharmacokinetics (PK) and Efficacy of AI-061, A 1:1 Co-formulation of AI-025 (Anti-PD-1) and ONC-392 (Anti-CTLA-4) Antibodies in Advanced Solid Tumors: An Open-Label Phase 1 Study (
PRESERVE-009
)
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
Adenocarcinoma
Anal cancer
Biliary tract cancer
Bladder cancer
Cancer
Cervical cancer
Clear cell renal cell carcinoma
Colorectal cancer
Endometrial cancer
Fallopian tube cancer
Gastric cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Melanoma
Non-small cell lung cancer
Oesophageal cancer
Primary peritoneal serous carcinoma
NSW
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre
QLD
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre
4215 - Southport - Tasman Oncology
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
5042 - Bedford Park - Southern Oncology Clinical Research Unit
NCT05363605
Advanced
Phase 1 / Phase 2
Terminated
A Phase 1/2 Study of [225Ac]-FPI-1966, [111In]-FPI-1967, and Vofatamab in Participants With FGFR3-expressing Advanced, Inoperable, Metastatic and/or Recurrent Solid Tumours (
FPI-1966-101
)
radioconjugate,FGFR3-targeting
Bladder cancer
Breast cancer
Colorectal cancer
Gastric cancer
Head and neck squamous cell carcinoma
Hepatocellular carcinoma
Lung cancer
Ovarian cancer
Solid tumour
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
WA
6150 - Murdoch - Fiona Stanley Hospital
NCT05359861
Advanced
Phase 2
Active not recruiting
A Randomized Phase 2 Trial of Atezolizumab and Bevacizumab in Combination With SRF388 or Placebo in Patients With Untreated Locally Advanced or Metastatic Hepatocellular Carcinoma (
SRF388-201
)
anti-IL27 monoclonal antibody
anti-PD-L1 monoclonal antibody
anti-VEGF monoclonal antibody
placebo
Hepatocellular carcinoma
VIC
3004 - Melbourne, Southbank - Alfred Health
3052 - Parkville - Royal Children's Hospital Melbourne
NCT05337137
Advanced
Phase 1 / Phase 2
Active not recruiting
A Phase 1/2, Safety Confirmation, Placebo-controlled, Randomized Study of Nivolumab in Combination With Relatlimab and Bevacizumab in Treatment-naive Advanced/Metastatic Hepatocellular Carcinoma (
RELATIVITY-106
)
anti-LAG3 monoclonal antibody
anti-PD-1 monoclonal antibody
anti-VEGF monoclonal antibody
placebo
Hepatocellular carcinoma
NSW
2050 - Camperdown - Chris O'Brien Lifehouse
VIC
3065 - Fitzroy - St Vincent's Hospital Melbourne
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre
SA
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre
WA
6009 - Nedlands - Linear Clinical Research
NCT05212922
Advanced
Phase 2
Withdrawn
An Open-Label, Non-Randomized, Multi-center Phase 2 Study of
YH001
in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer (NSCLC) and Hepatocellular Carcinoma (HCC)
anti-CTLA-4 monoclonal antibody
anti-PD-1 monoclonal antibody
Hepatocellular carcinoma
Non-small cell lung cancer
NSW
2170 - Liverpool - Liverpool Hospital
VIC
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong
Additional search terms:
API and Webpage URLs:
Copy /Bookmark
Filters
Recruitment Status
Recruiting (11)
Active not recruiting (4)
Not yet recruiting (1)
Terminated (1)
Withdrawn (1)
Recruitment Country and State
NSW (11)
VIC (9)
SA (7)
QLD (5)
WA (4)
NZ (4)
Phase
Phase 1 (9)
Phase 1 / Phase 2 (5)
Phase 2 (3)
Phase 3 (1)
Trial Type
Advanced (17)
Curative (1)
Cancer Therapy Class
PD-1/PD-L1
50%
PD-1
39%
VEGF
28%
PD-L1
22%
GPC3
17%
LAG3
17%
TIGIT
17%
CTLA4
17%
ER alpha
6%
oestrogen axis
6%
B7H3
6%
MET
6%
CDH17
6%
HIF2a
6%
IL-6
6%
PPAR-alpha
6%
GARP
6%
4-1BB
6%
FGFR
6%
FGFR3
6%
IL27
6%
Facility
2050 - Camperdown - Chris O'Brien Lifehouse (5)
2010 - Darlinghurst - St Vincent's Hospital Sydney - The Kinghorn Cancer Centre (4)
5000 - Adelaide - Royal Adelaide Hospital - Adelaide Cancer Centre (4)
NZ.1023 - Grafton - Auckland City Hospital - Cancer & Blood Research (4)
3004 - Melbourne, Southbank - Alfred Health (3)
6150 - Murdoch - Fiona Stanley Hospital (3)
3084 - Heidelberg - Austin Hospital Olivia Newton-John Cancer Centre (3)
2145 - Westmead - The Crown Princess Mary Cancer Centre - Westmead Hospital (2)
5042 - Bedford Park - Southern Oncology Clinical Research Unit (2)
4101 - South Brisbane - Mater Hospital Brisbane / ICON Cancer Centre (2)
5042 - Bedford Park - Flinders Medical Centre (2)
3065 - Fitzroy - St Vincent's Hospital Melbourne (2)
2109 - North Ryde - Macquarie University Hospital (1)
4102 - Woolloongabba - Integrated Clinical Oncology Network (ICON) Pty Ltd (1)
4066 - Auchenflower - Icon Cancer Centre at Wesley Hospital (1)
5037 - Kurralta Park - Icon Cancer Centre Adelaide (1)
2217 - Kogarah - St George Private Hospital (1)
2305 - New Lambton Heights - Hunter New England Cancer Centre - John Hunter Hospital (1)
2747 - Kingswood - Nepean Hospital - Nepean Cancer Care Centre (1)
3053 - Parkville - The Royal Women's Hospital and Institute of Maternal and Child Health (1)
3128 - Box Hill - Box Hill Hospital - Eastern Health (1)
4006 - Herston - The Royal Brisbane and Women's Hospital Cancer Centre (1)
4102 - Woolloongabba - Princess Alexandra Hospital (1)
4215 - Southport - Gold Coast University Hospital (1)
6009 - Nedlands - Sir Charles Gairdner Hospital - WA Cancer Centre (1)
NZ.6021 - Wellington - Capital & Coast District Health Board - Wellington Hospital (1)
NZ.8011 - Christchurch - Canterbury District Health Board - Christchurch Hospital Cancer Centre (1)
4215 - Southport - Tasman Oncology (1)
3052 - Parkville - Royal Children's Hospital Melbourne (1)
6009 - Nedlands - Linear Clinical Research (1)
2170 - Liverpool - Liverpool Hospital (1)
3220 - Geelong - Andrew Love Cancer Centre, University Hospital Geelong (1)
Cancer Type
Cancer
Gastrointestinal cancer
Hepatobiliary cancer
Hepatocellular carcinoma
Solid tumour
Upper gastrointestinal cancer
Thoracic cancer
Gastroesophageal cancer
Pancreatobiliary cancer
Gastric cancer
Gynaecological cancer
Head and neck cancer
Lung cancer
Pancreatic cancer
Respiratory tract cancer
Urogenital cancer
Breast cancer
Colorectal cancer
Lower gastrointestinal cancer
Ovarian cancer
Head and neck squamous cell carcinoma
Bladder cancer
Oesophageal cancer
Non-small cell lung cancer
Cervical cancer
Clear cell renal cell carcinoma
HPV-related cancer
HPV16-positive cancer
Kidney cancer
Male genital cancers
Melanoma
Viral-related cancer
Endometrial cancer
Biliary tract cancer
Prostate cancer
Sarcoma
Carcinoma
Epithelial Ovarian Cancer
High-grade serous carcinoma of the ovary, fallopian tube, and peritoneum
Breast adenocarcinoma
Exocrine pancreatic cancer
Pancreatic adenocarcinoma
Triple-negative breast cancer
Germ cell tumour
Non-seminoma
Squamous non-small-cell lung cancer
Testicular cancer
Yolk sac tumour
Castrate-resistant prostate cancer
High-grade serous ovarian cancer
Neuroendocrine carcinoma
Ovarian adenocarcinoma
Ovarian serous carcinoma
Platinum resistant ovarian cancer
Prostate adenocarcinoma
Small-cell lung cancer
Small-cell neuroendocrine carcinoma
Oesophageal squamous cell carcinoma
Cholangiocarcinoma
Colorectal adenocarcinoma
Oesophageal adenocarcinoma
Urothelial carcinoma
Adenocarcinoma
Anal cancer
Fallopian tube cancer
Peritoneal cancer
Primary peritoneal serous carcinoma
URLs for this search
API URL:
Copy
Bookmarkable URL:
Copy